A generic fixed dose combination drug of Sofosbuvir and Daclatasvir for treatment of Hepatitis C
Natco Pharma announced that it is the first company in India to launch under its brand Hepcinat Plus, the generic fixed dose combination of Sofosbuvir 400 mg and Daclatasvir 60mg Tablet, for the treatment of patients with chronic hepatitis C virus (HCV) infection.Natco has launched Hepcinat Plus at an MRP of Rs 17,500, for a bottle of 28 tablets.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
